LGND - CIK 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $49.36M | $97.05M | $49.58M | $137.85M | $78.80M | $54.59M |
| Capital expenditure | $452.00K | $1.82M | $3.52M | $17.92M | $8.76M | $4.46M |
| Investing cash flow | -$377.32M | -$143.66M | -$11.68M | $163.62M | $30.52M | $231.65M |
| Dividends paid | - | - | - | - | - | - |
LIGAND PHARMACEUTICALS INC reported operating cash flow of $49.36M for fiscal year 2025. That is down 49.1% from $97.05M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $60.73M (FY 2016) to $49.36M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $15.00M | $0.00 | $0.00 | $0.00 | $0.00 | $78.00M |
| Financing cash flow | $428.22M | $97.14M | -$59.95M | -$275.99M | -$137.76M | -$310.55M |